The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes in advanced urothelial cancer (UC) patients who experienced immune-related adverse events (irAEs) after immune checkpoint inhibitor monotherapy (ICI).
 
Gregory E. Sanda
No Relationships to Disclose
 
Julie M. Shabto
No Relationships to Disclose
 
Subir Goyal
No Relationships to Disclose
 
Yuan Liu
No Relationships to Disclose
 
Dylan J. Martini
No Relationships to Disclose
 
Bassel Nazha
Consulting or Advisory Role - Exelixis
 
Jacqueline T Brown
No Relationships to Disclose
 
Lauren Beth Yantorni
No Relationships to Disclose
 
Greta Russler
No Relationships to Disclose
 
Sarah Caulfield
No Relationships to Disclose
 
Shreyas S. Joshi
No Relationships to Disclose
 
Vikram M. Narayan
No Relationships to Disclose
 
Haydn Kissick
No Relationships to Disclose
 
Kenneth Ogan
No Relationships to Disclose
 
Viraj A. Master
Honoraria - Ethicon
 
Bradley Curtis Carthon
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Eisai; Immunomedics
Research Funding - Alkermes (Inst); MedImmune (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Omer Kucuk
No Relationships to Disclose
 
Mehmet Asim Bilen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Nektar (Inst); Peloton Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)